Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
NCT02202356 is registered in ClinicalTrials.gov with Alios Biopharma Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
- Lead sponsor
- Alios Biopharma Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 23, 2014
- Completion date
- February 15, 2018
- Enrollment
- 183 (actual)
- Sites
- 77
Conditions
As the registry lists them; a condition with its own page is linked.